Verastem Oncology to Present at Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--May 1, 2025--
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate and present at the following investor conferences in May:
A live webcast of the fireside chats can be accessed under events on Verastem Oncology's website at www.verastem.com. A replay of the webcasts will be archived on the website for approximately 90 days following the presentation.
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Our pipeline is focused on novel small-molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition. For more information, please visit www.verastem.com and follow us on LinkedIn.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250501095515/en/
CONTACT: For Investor and Media Inquiries:
Julissa Viana
Vice President, Corporate Communications,
Investor Relations & Patient Advocacy
[email protected]
[email protected]
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS
INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH ONCOLOGY
SOURCE: Verastem Oncology
Copyright Business Wire 2025.
PUB: 05/01/2025 07:30 AM/DISC: 05/01/2025 07:32 AM
http://www.businesswire.com/news/home/20250501095515/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
33 minutes ago
- Wall Street Journal
Dow, S&P 500, Nasdaq All Positive on the Year Once Again
All three major U.S. stock indexes closed in positive year-to-date territory simultaneously for the first time since Feb. 21. The S&P 500, Nasdaq Composite, and Dow Jones Industrial Average all rose by 1%, or more, during Friday's trading. Stocks have been volatile through weeks of tariff news, but have recovered losses from recent months. This year, the S&P 500 is up 2%, the Nasdaq is up 1.1% and the Dow is up 0.5%, according to Dow Jones Market Data.
Yahoo
36 minutes ago
- Yahoo
Alpha Cognition Inc. Common Stock (ACOG): A Bull Case Theory
We came across a bullish thesis on Alpha Cognition Inc. Common Stock (ACOG) by anygal on r/investing on Reddit. In this article, we will summarize the bulls' thesis on ACOG. Alpha Cognition Inc. Common Stock (ACOG)'s share was trading at $9.33 as of 30th May. ACOG's forward P/E was 26.88 according to Yahoo Finance. A chemist in a laboratory analyzing data from the various therapeutic tests conducted. Alpha Cognition Inc. (NASDAQ: ACOG) represents a potentially overlooked opportunity in the Alzheimer's treatment space, having recently launched its oral drug, Zunveyl, at the end of March. With a current market cap of $150 million and $45 million in cash, the company is targeting the underserved segment of the Alzheimer's population—specifically, the 50% of patients in long-term care (LTC) not taking any current medications due to severe side effects. Unlike other galantamine-based drugs, Zunveyl significantly slows disease progression and improves short-term memory with a markedly better safety profile—only one serious side-effect case was reported in its Phase 3 trials, versus a 50% rate seen in traditional options. The drug's Medicare coverage further eases affordability, lowering monthly out-of-pocket costs to $30–$190. Initial demand appears promising, with nearly 500 patients starting treatment in the first two weeks of launch. Even a modest 1% market penetration into the LTC segment could yield $135 million in annual revenue, with $67.5 million in net income assuming 50% margins. A 5% penetration would put net income at $675 million, dwarfing the current valuation. Alpha Cognition has also secured a distribution deal with a major Chinese pharmaceutical firm, creating a royalty-based revenue stream in Asia. While the upside is substantial, key risks remain—most notably, the emergence of unforeseen serious side effects post-launch, which could lead to FDA scrutiny or suspension of sales. Still, the market's underreaction and the company's positioning as a safer, effective alternative in a high-need space make ACOG a high-upside, high-conviction bet for risk-tolerant investors. Previously, we have covered ACOG in March 2025 wherein we summarized a by BullishDoctor on Twitter. The user highlighted that Alpha Cognition Inc.'s drug ZUNVEYL addressed the major side effects of existing Alzheimer's treatments, making it highly tolerable and poised for adoption in long-term care facilities, a $2 billion market. The company was pre-revenue but launched in March 2025 with strong physician support, a nearly complete sales force, and promising catalysts like a Phase 4 study and sublingual formulation, projecting breakeven within three years. Since our last coverage, the stock is up 61% as of 30th May. Alpha Cognition Inc. Common Stock (ACOG) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 8 hedge fund portfolios held ACOG at the end of the first quarter which was 10 in the previous quarter. While we acknowledge the potential of ACOG as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Why Shopify Stock Popped Today
A Wells Fargo analyst raised their price target on Shopify's stock today. They called the company their "signature pick" and believe it could be a lesser-known beneficiary of the AI revolution. Home to its Shopify Magic and Sidekick solutions, Shopify looks more poised to thrive amid AI's rise, rather than be disrupted by it. 10 stocks we like better than Shopify › Shares of North America's leading commerce enabler, Shopify (NASDAQ: SHOP), were 6% higher as of 3:30 p.m. ET Friday, according to data provided by S&P Global Market Intelligence. This rise stems from an analyst at Wells Fargo raising their price target on the stock from $107 to $125, naming Shopify a "signature pick." Although Nvidia, Palantir, OpenAI, and others capture most of the artificial intelligence (AI) fanfare, the analyst believes Shopify could prove to be a thematic AI story -- and I'd agree. In April this year, a leaked memo from Chief Executive Officer Tobi Lütke went viral. In it, he stated, "Before asking for more headcount and resources, teams must demonstrate why they cannot get what they want done using AI." Although this focuses on incorporating AI into Shopify's operations, the quote highlights that AI will be at the heart of what the company does going forward, whether internally or through its products. In 2023, the company launched Shopify Magic, a toolbox of AI-powered solutions (think AI-generated product descriptions or email campaigns, automated chat help, or image editing). Then, it launched Sidekick -- an AI-driven commerce assistant -- in 2024 to help with areas such as inventory optimization, pricing strategies, and gathering business insights. Just last quarter, Shopify launched This tool enables merchants to source products more effectively, allowing them to navigate the complex tariff environment in real time. Adding over 600 new product features for its merchants in the last two years alone, Shopify appears likely to remain an AI innovator rather than a disruptee, in my opinion. Though Shopify stock isn't cheap at 83 times cash from operations, its growth potential remains massive, holding only a 2% market share in its core geographies. Before you buy stock in Shopify, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Shopify wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $674,395!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $858,011!* Now, it's worth noting Stock Advisor's total average return is 997% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Wells Fargo is an advertising partner of Motley Fool Money. Josh Kohn-Lindquist has positions in Nvidia and Shopify. The Motley Fool has positions in and recommends Nvidia, Palantir Technologies, and Shopify. The Motley Fool has a disclosure policy. Why Shopify Stock Popped Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
